ID   RT112-CP
AC   CVCL_B7BP
DR   cancercelllines; CVCL_B7BP
DR   Wikidata; Q114312927
RX   PubMed=2144165;
CC   Population: Caucasian.
CC   Doubling time: 21.5 +- 1.5 hours (PubMed=2144165).
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Gene fusion; HGNC; 3690; FGFR3 + HGNC; 11524; TACC3; Name(s)=FGFR3-TACC3 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser183Ter (c.548C>G); ClinVar=VCV000634701; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1670 ! RT-112
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 05-10-23; Version: 5
//
RX   PubMed=2144165; DOI=10.1016/0277-5379(90)90133-e;
RA   Walker M.C., Povey S., Parrington J.M., Riddle P.N., Knuechel R.,
RA   Masters J.R.W.;
RT   "Development and characterization of cisplatin-resistant human
RT   testicular and bladder tumour cell lines.";
RL   Eur. J. Cancer 26:742-747(1990).
//